Literature DB >> 15260970

Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Gunter Meister1, Markus Landthaler, Agnieszka Patkaniowska, Yair Dorsett, Grace Teng, Thomas Tuschl.   

Abstract

Argonaute proteins associate with small RNAs that guide mRNA degradation, translational repression, or a combination of both. The human Argonaute family has eight members, four of which (Ago1 through Ago4) are closely related and coexpressed in many cell types. To understand the biological function of the different Ago proteins, we set out to determine if Ago1 through Ago4 are associated with miRNAs as well as RISC activity in human cell lines. Our results suggest that miRNAs are incorporated indiscriminately of their sequence into Ago1 through Ago4 containing microRNPs (miRNPs). Purification of the FLAG/HA-epitope-tagged Ago containing complexes from different human cell lines revealed that endonuclease activity is exclusively associated with Ago2. Exogenously introduced siRNAs also associate with Ago2 for guiding target RNA cleavage. The specific role of Ago2 in guiding target RNA cleavage was confirmed independently by siRNA-based depletion of individual Ago members in combination with a sensitive positive-readout reporter assay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15260970     DOI: 10.1016/j.molcel.2004.07.007

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  792 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  An antiviral RISC isolated from Tobacco rattle virus-infected plants.

Authors:  Jessica J Ciomperlik; Rustem T Omarov; Herman B Scholthof
Journal:  Virology       Date:  2011-01-26       Impact factor: 3.616

Review 3.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 4.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

5.  Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a.

Authors:  Jonathan D Verrier; Pierre Lau; Lynn Hudson; Alexander K Murashov; Rolf Renne; Lucia Notterpek
Journal:  Glia       Date:  2009-09       Impact factor: 7.452

Review 6.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

7.  Genome-wide analysis of mRNAs regulated by Drosha and Argonaute proteins in Drosophila melanogaster.

Authors:  Jan Rehwinkel; Pavel Natalin; Alexander Stark; Julius Brennecke; Stephen M Cohen; Elisa Izaurralde
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

8.  RNase III-independent microRNA biogenesis in mammalian cells.

Authors:  Thomas Maurin; Demián Cazalla; Shiuan Yang; Diane Bortolamiol-Becet; Eric C Lai
Journal:  RNA       Date:  2012-10-24       Impact factor: 4.942

9.  Genome-wide analysis of mir-548 gene family reveals evolutionary and functional implications.

Authors:  Tingming Liang; Li Guo; Chang Liu
Journal:  J Biomed Biotechnol       Date:  2012-10-02

10.  Inefficient SRP interaction with a nascent chain triggers a mRNA quality control pathway.

Authors:  Andrey L Karamyshev; Anna E Patrick; Zemfira N Karamysheva; Dustin S Griesemer; Henry Hudson; Sandra Tjon-Kon-Sang; IngMarie Nilsson; Hendrik Otto; Qinghua Liu; Sabine Rospert; Gunnar von Heijne; Arthur E Johnson; Philip J Thomas
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.